🚨BIG news 🚨 The ICR has received the Queen Elizabeth Prize for Higher and Further Education for our groundbreaking radiotherapy research. This work has improved cancer care worldwide—through advanced techniques, landmark trials, and training the next generation of oncologists. #QEdPrizes

Sign up for our webinar with @bursturology.bsky.social on Thursday 23 October, 09.00 to hear experts discuss the use of systemic anti-cancer treatment in metastatic prostate cancer and submit questions in advance 👇 www.natcan.org.uk/events/webin... See you there! @alison-tree.bsky.social

📢 The NPCA State of the Nation Report 2025 is OUT! Find the report, supplementary documents & provider results here www.natcan.org.uk/reports/npca... @natcan-news.bsky.social @hqip.bsky.social @prostatecanceruk.bsky.social @alison-tree.bsky.social @nhsengland.bsky.social Please share!

New comment piece by me & colleagues in @bmj.com on the using health data for research in UK Processes are so complex and so slow now that less research is happening and we are wasting the enormous potential of the NHS to drive innovation www.bmj.com/content/390/...

@alison-tree.bsky.social @ccparker.bsky.social #prostatecancer #pcsm

Excited to see the MARS trial highlighted here @cihangani.bsky.social @elekta.com @mrlconsortium.bsky.social @momentumstudy.bsky.social

Pleasure to be at the MRI in RT symposium at USZ @mguckenberger.bsky.social Meme of the day goes to Luca Boldrini

We had the SABR bone and nodes workshop today. @uksabr.bsky.social in collaboration with the RCR. Lots of discussion & learning for all within the SABR MDT. Collaboration at its best. Thank you to all those that attended and especially the speakers. @alison-tree.bsky.social @pattydiezh.bsky.social

Happy to share our review on hypo- and ultra-hypofractionation for prostate cancer radiotherapy, just published in Seminars in Radiation Oncology @alison-tree.bsky.social @harshanigreen.bsky.social Full-text link: authors.elsevier.com/a/1lFrI3lXQo...

Fantastic opening plenary at #UKOF25 by @charlesswanton.bsky.social Cancer initiation is not a simple matter of DNA damage from carcinogens. Forget everything you learned before!

💥 Our Transformational Impact Awards are now OPEN! 💥 This call supports our larger-scale research investments covering high-quality discovery science through to translational and clinical research. Submission deadline: 1pm, 23 September 2025 Apply now 👉 buff.ly/eCSnnCM

We are looking for two exceptional consultant uro-oncologists to come and join our team in Sutton. Please see further details 👇 www.royalmarsden.nhs.uk/current-vaca...

A great opportunity to work in cutting edge #clinicaltrials within a fun multidisciplinary team @notchonctrainees.bsky.social

Great news! If you have an idea for a new radiotherapy trial, please find the email below

Excited to see the HERMES trial results in print www.sciencedirect.com/science/arti... Small trial but toxicity of 2 fractions looks promising at 24/27 Gy, no GI tox of G2 or higher out to 12 weeks @momentumstudy.bsky.social @icr.ac.uk

What could be better than 5 days in Verona in October, learning about prostate cancer? Comprehensive multidisciplinary programme aimed at oncologists, urologists, radiologists and anyone else involved in treated prostate cancer. Spread the word!

Encouraging data on safety of 5-fraction SBRT for post-prostatectomy recurrence 👇

Don’t forget to register for the annual UK Oncology forum, which is FREE to attend. Breakout sessions covering topics including prostate cancer and radiotherapy, including Dr Ben O’Leary @icr.ac.uk, Dr Rovel Colaco, Dr Katie Spencer and Prof Stefanie Corradini oncology-forum.co.uk/register/

Congratulations to Professor Faivre-Finn on the ESTRO Breur award, and using your platform to encourage us all to address gender inequality in academic radiation oncology 👏 #ESTRO25

Congratulations to @montefiored.bsky.social for a great presentation of the ARISTOTLE trial 👏. Always learn a lot from an RCT, sometimes not the things you were expecting to learn #ESTRO2025

Significant benefit to focal boost in prostate cancer out to 10 years in FLAME trial #ESTRO2025 Fifteen percent of men avoid further treatment just due to the boost 🏆

Congratulations @montefiored.bsky.social & team 👏🏽 I remember talking to you in clinic about this as a registrar. Great to see the results and the impact for patients #ESTRO25 @thelancetoncol.bsky.social

Great summary from Piet Ost, summarising what we know about systemic therapy +/- SBRT (and vice versa) in prostate oligomets #ESTRO25

HYPO-RT-PC 10 year data presented at #ESTRO2025. Seven fractions def non-inferior to 39 fractions, suggestion that 7 fractions might even be more likely to cure?

Exciting data presented in ESTRO 2025 plenary: 5 fraction adjuvant breast RT (26 Gy) at least as good (and possibly better?) than 15 fractions @icr.ac.uk #ESTRO2025

⚠️ Another key finding of this study is that higher rates of metastatic prostate cancer were seen in regions with lower rates of prostate cancer diagnosis overall which may be linked to variation in the use of PSA testing.

#Radonc representation on @NCCN Treatment Guideline Committees is <10%, even for committees that recommend #radiation. Additionally, certain institutions have nominated relatively few ☢️👩‍⚕️ for their designated slots. Glad to see this 📰 finally published. www.advancesradonc.org/article/S245...

Impt paper from @npca-natcan.bsky.social-geographic variation in prostate cancer diagnosis bmjoncology.bmj.com/content/4/1/... Areas with the HIGHEST risk of metastatic disease have the LOWEST incidence of all prostate cancer. Prostate cancer is curable if caught early @prostatecanceruk.bsky.social

The absolute callousness of announcing a 44% trade tariff against Myanmar this week, of all weeks.

🚨out today🚨 🎙️ Part 2 of our conversation with the excellent @achoud72.bsky.social on bladder preservation in bladder cancer🙌🏽 Once again making the case for bladder radiotherapy 🥁 Enjoy @rcradiologists.bsky.social www.buzzsprout.com/2342317/epis...

[1/7] 🔎 Lets take a closer look at the results of the @prostateuk.bsky.social funded TRAP trial, led by @alison-tree.bsky.social and team, and published this week in @ijrobp.bsky.social 🧵

If I could have my time over again…I still wouldn’t be able to get this job, but you might! What an inspirational duo to work with @cec-icr.bsky.social @icr.ac.uk

Thanks to @prostatecanceruk.bsky.social for their unwavering support through this trial. Exciting to see radiotherapy make an impact, even in metastatic prostate cancer

Really shameful that more than 2 years after we learned that Abiraterone, an inexpensive medicine, saves lives, it is STILL not available in the English NHS. Thanks @prostatecanceruk.bsky.social for highlighting the struggle many men, and their doctors, are facing. www.bbc.com/news/article...

NEW: Keir Starmer says the government will be abolishing NHS England and NHS will be brought back under direct political control. Big moment. In effect a dramatic and large scale NHS reorganisation.

Superstar team on the rise 👇 Ones to watch @icr.ac.uk @drannawilkins.bsky.social

⚠️Do you or someone you know want to come and work with me and the fantastic @npca-natcan.bsky.social @natcan-news.bsky.social teams based @collegeofsurgeons.bsky.social? Our oncological clinical lead is the super @alison-tree.bsky.social 😁. Interested? Apply here www.jobs.ac.uk/job/DMB374/c...

TRAP trial results now out @ijrobp.bsky.social funded by @prostatecanceruk.bsky.social Men oligoprogressing on Abi/Enza for CRPC, nearly 40% progression-free 1 year after SBRT. No significant side effects due to radiotherapy. www.sciencedirect.com/science/arti...

Calling academic friends. We could have seen this coming but I failed to plan ahead. What is the best alternative to Pubmed?

If you are reeling from Trump & Vance's disgusting performance towards Zelensky last night, might you consider donating to www.hospiceukraine.com, the tiny charity I set up with Henry Marsh to support local Ukrainian palliative care teams? We delivered this Land Rover to a rural hospice in Dec...

Dear Volodymyr Zelenskyy, dear Ukrainian friends, you are not alone.

More details about the NPCA can be found here buff.ly/4kiLhxy and reports buff.ly/4klANxy and publications buff.ly/4kn1HF1. Enquiries can be made to [email protected]. Closing date 31st March 2025. Please share widely @alison-tree.bsky.social @natcan-news.bsky.social @prostateukprofs.bsky.social

Total amount of pattern 4 provides superior prognostic information than grade groups. Further research should investigate the best pattern 4 quantification method. www.auajournals.org/doi/10.1097/...

👇

Here is my top educational tip to trainees in #oncology: read review articles. Collect & share them with your colleagues and build an e-library of all the key topics. Distillation of current knowledge & data (by key opinion leaders) into bite size pieces is priceless

Want to learn more about prostate radiotherapy contouring? Register for the ESTRO prostate contouring course- two evening sessions with me and @dannyvesprini.bsky.social More info here www.estro.org/Courses/2025...

Welcome to Bluesky @drandrewloblaw!

📢🎙️Tune in to this must-listen podcast episode with Anna Kirby 👇👇👇@trialstribspod.bsky.social

Exciting news! Our Red Journal invited editorial on sim-free RT is now available! @ijrobp.bsky.social @drdavidpalma.bsky.social Grateful for the opportunity to contribute to this discussion! Check it out here: authors.elsevier.com/c/1kYHc1Hx52... #simfreeRT #radiotherapy #palliativeRT #OpenAccess

Great to see this report from UKRI published today. It contains some concrete proposals for reversing the decline in UK clinical academia. Now they just need to be delivered! www.ukri.org/wp-content/u...